- Home
- ERAS vs KELYA Comparison
ERAS vs KELYA Comparison
Compare ERAS & KELYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- KELYA
- Stock Information
- Founded
- ERAS 2018
- KELYA 1946
- Country
- ERAS United States
- KELYA United States
- Employees
- ERAS 129
- KELYA N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- KELYA Professional Services
- Sector
- ERAS Health Care
- KELYA Consumer Discretionary
- Exchange
- ERAS Nasdaq
- KELYA Nasdaq
- Market Cap
- ERAS 413.6M
- KELYA 403.0M
- IPO Year
- ERAS 2021
- KELYA N/A
- Fundamental
- Price
- ERAS $1.42
- KELYA $12.19
- Analyst Decision
- ERAS Strong Buy
- KELYA Buy
- Analyst Count
- ERAS 6
- KELYA 1
- Target Price
- ERAS $4.83
- KELYA $25.00
- AVG Volume (30 Days)
- ERAS 1.1M
- KELYA 278.8K
- Earning Date
- ERAS 08-11-2025
- KELYA 08-07-2025
- Dividend Yield
- ERAS N/A
- KELYA 2.43%
- EPS Growth
- ERAS N/A
- KELYA N/A
- EPS
- ERAS N/A
- KELYA N/A
- Revenue
- ERAS N/A
- KELYA $4,451,600,000.00
- Revenue This Year
- ERAS N/A
- KELYA $8.06
- Revenue Next Year
- ERAS N/A
- KELYA $4.08
- P/E Ratio
- ERAS N/A
- KELYA N/A
- Revenue Growth
- ERAS N/A
- KELYA N/A
- 52 Week Low
- ERAS $1.01
- KELYA $10.80
- 52 Week High
- ERAS $3.45
- KELYA $23.81
- Technical
- Relative Strength Index (RSI)
- ERAS 53.15
- KELYA 56.52
- Support Level
- ERAS $1.42
- KELYA $12.17
- Resistance Level
- ERAS $1.58
- KELYA $12.87
- Average True Range (ATR)
- ERAS 0.10
- KELYA 0.32
- MACD
- ERAS 0.01
- KELYA 0.06
- Stochastic Oscillator
- ERAS 68.65
- KELYA 70.06
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About KELYA Kelly Services Inc.
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.